Ashley Little
Medical · Bogalusa, LANPI 1770705121
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 180 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$559
- AstraZeneca$322
- AbbVie$230
- Novo Nordisk$228
- Boehringer Ingelheim$161
- Amgen$158
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,980100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 39 | $559 |
| AstraZeneca | 20 | $322 |
| AbbVie | 13 | $230 |
| Novo Nordisk | 12 | $228 |
| Boehringer Ingelheim | 11 | $161 |
| Amgen | 9 | $158 |
| Dexcom, Inc. | 8 | $157 |
| GSK | 7 | $120 |
| Exact Sciences | 5 | $97 |
| Sumitomo Pharma America, Inc. | 7 | $91 |
| Merck | 5 | $76 |
| Pfizer | 4 | $76 |
| Novartis | 4 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Johnson & Johnson | 2 | $61 |
| UCB, Inc. | 3 | $59 |
| Bayer | 3 | $50 |
| Dynavax Technologies Corporation | 2 | $41 |
| Abbott | 2 | $39 |
| Verona Pharma, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Mylan Specialty L.p. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 4 | $29 |
| Vanda Pharmaceuticals Inc. | 2 | $29 |
| Sanofi | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Vertex | 1 | $14 |
How this compares
$2,980 in reported general payments places this provider in the 75th percentile of 253 medical providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 100 | $125,950 |
| JardianceEmpagliflozin | 82 | $99,825 |
| RybelsusSemaglutide | 42 | $70,622 |
| JanuviaSitagliptin Phosphate | 57 | $58,541 |
| TrulicityDulaglutide | 58 | $55,533 |
| OzempicSemaglutide | 29 | $29,159 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,671 |
| Repatha SureclickEvolocumab | 30 | $20,638 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $13,596 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $11,080 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $10,222 |
| MyrbetriqMirabegron | 15 | $9,178 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $8,332 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,646 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 12 | $3,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $559 | $181,483158 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $161 | $110,04696 claims |
| Novo NordiskRybelsus, Ozempic | $228 | $99,78171 claims |
| MerckJanuvia | $76 | $58,54157 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $120 | $32,31743 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $32 | $13,59617 claims |
| Esperion Therapeutics, Inc.Nexlizet | $20 | $11,08021 claims |
| AbbVieSynthroid | $230 | $91718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 253 medical providers in Louisiana.
Other medical in Bogalusa
- Kristi RobertBaton Rouge$486K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Rachel RhinehartJefferson$16K
- Sydney FussellCovington$16K
- Thomas BriscoeLafayette$13K
- Seth HendrixShreveport$12K
- Jessica PelusoNatchitoches$12K
- Heather RoanBossier City$11K
- Emily FerraraBaton Rouge$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.